Viveque Egsgaard Nielsen

Stimulation With 0.3-mg Recombinant Human Thyrotropin Prior to Iodine 131 Therapy to Improve the Size Reduction of Benign Nontoxic Nodular Goiter

Viveque Egsgaard Nielsen, Steen Joop Bonnema, Henrik Boel-Jørgensen et al. · Archives of Internal Medicine · 2006 · 95 citations

Improvement of Goiter Volume Reduction after 0.3 mg Recombinant Human Thyrotropin-Stimulated Radioiodine Therapy in Patients with a Very Large Goiter: A Double-Blinded, Randomized Trial

Steen Joop Bonnema, Viveque Egsgaard Nielsen, Henrik Boel-Jørgensen et al. · The Journal of Clinical Endocrinology & Metabolism · 2007 · 89 citations · Full text

Transient Goiter Enlargement after Administration of 0.3 mg of Recombinant Human Thyrotropin in Patients with Benign Nontoxic Nodular Goiter: A Randomized, Double-Blind, Crossover Trial

Viveque Egsgaard Nielsen, Steen Joop Bonnema, László Hegedüs · The Journal of Clinical Endocrinology & Metabolism · 2006 · 61 citations · Full text

Recombinant Human Thyrotropin-Stimulated Radioiodine Therapy of Large Nodular Goiters Facilitates Tracheal Decompression and Improves Inspiration

Steen Joop Bonnema, Viveque Egsgaard Nielsen, Henrik Boel-Jørgensen et al. · The Journal of Clinical Endocrinology & Metabolism · 2008 · 53 citations

Recombinant Human Thyrotropin Markedly Changes the¹³¹I Kinetics during¹³¹I Therapy of Patients with Nodular Goiter: An Evaluation by a Randomized Double-Blinded Trial

Viveque Egsgaard Nielsen, Steen Joop Bonnema, Henrik Boel-Jørgensen et al. · The Journal of Clinical Endocrinology & Metabolism · 2005 · 50 citations

Translational Medicine, Nuclear Medicine, Randomized Double-blinded Trial +14